120 related articles for article (PubMed ID: 11225990)
21. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
[TBL] [Abstract][Full Text] [Related]
22. A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44.
Godelaine D; Carrasco J; Brasseur F; Neyns B; Thielemans K; Boon T; Van Pel A
Cancer Immunol Immunother; 2007 Jun; 56(6):753-9. PubMed ID: 17096150
[TBL] [Abstract][Full Text] [Related]
23. Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2.
Ma W; Germeau C; Vigneron N; Maernoudt AS; Morel S; Boon T; Coulie PG; Van den Eynde BJ
Int J Cancer; 2004 May; 109(5):698-702. PubMed ID: 14999777
[TBL] [Abstract][Full Text] [Related]
24. New MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A1 tumor cells.
Kobayashi T; Lonchay C; Colau D; Demotte N; Boon T; van der Bruggen P
Tissue Antigens; 2003 Nov; 62(5):426-32. PubMed ID: 14617050
[TBL] [Abstract][Full Text] [Related]
25. A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion.
Zorn E; Hercend T
Eur J Immunol; 1999 Feb; 29(2):602-7. PubMed ID: 10064076
[TBL] [Abstract][Full Text] [Related]
26. A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes.
Schultz ES; Zhang Y; Knowles R; Tine J; Traversari C; Boon T; van der Bruggen P
Tissue Antigens; 2001 Feb; 57(2):103-9. PubMed ID: 11260504
[TBL] [Abstract][Full Text] [Related]
27. A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes.
Luiten R; van der Bruggen P
Tissue Antigens; 2000 Feb; 55(2):149-52. PubMed ID: 10746786
[TBL] [Abstract][Full Text] [Related]
28. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.
Coulie PG; Lehmann F; Lethé B; Herman J; Lurquin C; Andrawiss M; Boon T
Proc Natl Acad Sci U S A; 1995 Aug; 92(17):7976-80. PubMed ID: 7644523
[TBL] [Abstract][Full Text] [Related]
29. Construction and characterization of a recombinant adenovirus directing expression of the MAGE-1 tumor-specific antigen.
Reed DS; Romero P; Rimoldi D; Cerottini JC; Schaack J; Jongeneel CV
Int J Cancer; 1997 Sep; 72(6):1045-55. PubMed ID: 9378539
[TBL] [Abstract][Full Text] [Related]
30. Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family.
Tanzarella S; Russo V; Lionello I; Dalerba P; Rigatti D; Bordignon C; Traversari C
Cancer Res; 1999 Jun; 59(11):2668-74. PubMed ID: 10363990
[TBL] [Abstract][Full Text] [Related]
31. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.
Coulie PG; Karanikas V; Lurquin C; Colau D; Connerotte T; Hanagiri T; Van Pel A; Lucas S; Godelaine D; Lonchay C; Marchand M; Van Baren N; Boon T
Immunol Rev; 2002 Oct; 188():33-42. PubMed ID: 12445279
[TBL] [Abstract][Full Text] [Related]
32. Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules.
So T; Hanagiri T; Chapiro J; Colau D; Brasseur F; Yasumoto K; Boon T; Coulie PG
Cancer Immunol Immunother; 2007 Feb; 56(2):259-69. PubMed ID: 16758204
[TBL] [Abstract][Full Text] [Related]
33. TNF-mediated toxicity after massive induction of specific CD8+ T cells following immunization of mice with a tumor-specific peptide.
Bilsborough J; Uyttenhove C; Colau D; Bousso P; Libert C; Weynand B; Boon T; van den Eynde BJ
J Immunol; 2002 Sep; 169(6):3053-60. PubMed ID: 12218121
[TBL] [Abstract][Full Text] [Related]
34. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
[TBL] [Abstract][Full Text] [Related]
35. The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses.
Sartorius R; Pisu P; D'Apice L; Pizzella L; Romano C; Cortese G; Giorgini A; Santoni A; Velotti F; De Berardinis P
J Immunol; 2008 Mar; 180(6):3719-28. PubMed ID: 18322177
[TBL] [Abstract][Full Text] [Related]
36. A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy.
Ma W; Vigneron N; Chapiro J; Stroobant V; Germeau C; Boon T; Coulie PG; Van den Eynde BJ
Int J Cancer; 2011 Nov; 129(10):2427-34. PubMed ID: 21207413
[TBL] [Abstract][Full Text] [Related]
37. The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection.
Brändle D; Bilsborough J; Rülicke T; Uyttenhove C; Boon T; Van den Eynde BJ
Eur J Immunol; 1998 Dec; 28(12):4010-9. PubMed ID: 9862337
[TBL] [Abstract][Full Text] [Related]
38. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
39. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene.
Guilloux Y; Lucas S; Brichard VG; Van Pel A; Viret C; De Plaen E; Brasseur F; Lethé B; Jotereau F; Boon T
J Exp Med; 1996 Mar; 183(3):1173-83. PubMed ID: 8642259
[TBL] [Abstract][Full Text] [Related]
40. Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma.
Valmori D; Dutoit V; Rubio-Godoy V; Chambaz C; Liénard D; Guillaume P; Romero P; Cerottini JC; Rimoldi D
Cancer Res; 2001 Jan; 61(2):509-12. PubMed ID: 11212242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
